.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Army
Fish and Richardson
Fuji
Healthtrust
Chubb
UBS
McKesson
Cerilliant
Federal Trade Commission

Generated: September 25, 2017

DrugPatentWatch Database Preview

Elbasvir; grazoprevir - Generic Drug Details

« Back to Dashboard

What are the generic sources for elbasvir; grazoprevir and what is the scope of elbasvir; grazoprevir patent protection?

Elbasvir; grazoprevir
is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Elbasvir; grazoprevir has eighty-four patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for Generic Name: elbasvir; grazoprevir

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list53
Drug Prices:see low prices
DailyMed Link:elbasvir; grazoprevir at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: elbasvir; grazoprevir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,654Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors► Subscribe
9,090,661Inhibitors of hepatitis C virus replication► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: elbasvir; grazoprevir

Country Document Number Estimated Expiration
Hong Kong1160359► Subscribe
World Intellectual Property Organization (WIPO)2010111483► Subscribe
Eurasian Patent Organization201171174► Subscribe
Spain2392611► Subscribe
Spain2491090► Subscribe
World Intellectual Property Organization (WIPO)2010011566► Subscribe
Singapore10201402969Q► Subscribe
TaiwanI441638► Subscribe
CroatiaP20160476► Subscribe
Costa Rica20110089► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELBASVIR; GRAZOPREVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0160050Estonia► Subscribe(93) SZ 65861 01, 01.04.2016 (93) CH 65861 01, 01.04.2016
0858Netherlands► SubscribePRODUCT NAME: ELBASVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1119 20160726
2017000002Germany► SubscribePRODUCT NAME: GRAZOPREVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON.; REGISTRATION NO/DATE: EU/1/16/1119 20160722
2016 00070Denmark► SubscribePRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
0160050 00207Estonia► SubscribePRODUCT NAME: ELBASVIIR;REG NO/DATE: EU/1/16/1119 26.07.2016
2016048Lithuania► SubscribePRODUCT NAME: ELBASVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
2016 00069Denmark► SubscribePRODUCT NAME: ELBASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
0857Netherlands► SubscribePRODUCT NAME: GRAZOPREVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1119 20160726
2017000001Germany► SubscribePRODUCT NAME: ELBASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1119 20160722
2016049Lithuania► SubscribePRODUCT NAME: GRAZOPREVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
US Department of Justice
Moodys
Deloitte
Teva
Covington
UBS
Baxter
Boehringer Ingelheim
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot